Momentum Back At Cipla In Q2 But Albuterol Delayed In US
Executive Summary
Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.
You may also be interested in...
Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
Cipla To Recalibrate US Investments
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business
Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”